spacer
home > ebr > spring 2018 > therapy at work
PUBLICATIONS
European Biopharmaceutical Review

Therapy at Work

EBR: What is cell therapy?

Dr Daniel Shelly: The use of living human cells as therapeutic treatments can replace lost functionality or introduce a novel function (eg chimeric antigen receptor T-cells to attack tumours). Cell therapies are often classified as either autologous or allogeneic. Autologous cells are obtained from, transformed, and given back to the individual patient, whereas allogeneic cells are sourced from a single donor, grown in large numbers, transformed, and given to multiple patients.

Numerous methods of transformation exist such as using peptides to activate immune cells, using viral vectors to introduce new genetic functions, or gene editing (CRISPR-Cas9) to enhance cellular function. The cell therapy industry is currently at a turning point, driven by significant advances on many fronts, such as a significant amount of product approvals with several more to come, a regulatory recognition of the unique nature of the sector, a financial maturity and investor interest, and finally a general public awareness and interest.

Despite these advances, the sector still needs to optimise several key areas such as manufacture, storage (cryopreservation), formulation, and distribution of such products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Daniel Shelly is Director of business development at Albumedix, responsible for business development and out-licensing of the company’s core technologies and recombinant albumin products for manufacture, stabilisation, and formulation of small molecule, peptide, protein, viral, and cell therapeutics. He spent 10 years in cell culture, vaccine, and gene therapy clinical development and manufacturing. Daniel has authored several peerreviewed articles and book chapters and is an Adjunct Professor in the University of Cincinnati, US, clinical master’s programme, teaching biologics discovery and biotechnology management. He has degrees from Lehigh University (BA), US, The College of William and Mary (MA), US, Florida State (PhD), US, and the University of Cincinnati (MBA), US. Daniel did his post doctorate at the University of California, US, winning the APS Physiological Genomics Fellowship and a National Institutes of Health National Research Service Award.
spacer
Dr Daniel Shelly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI and CSP Technologies, Inc. Announce Strategic Collaboration for Breakthrough Activ-BlisterTM Solutions

Philadelphia, PA & Auburn, AL – September 17, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce its exclusive collaboration agreement with CSP Technologies, Inc. for U.S. clinical trials and stability testing utilizing Activ-BlisterTM packaging solutions, which help protect and promote speed-to-market for pharmaceutical and medical device products with heightened susceptibility to moisture and gases, especially oxygen.
More info >>

White Papers

Contemporary Issues in Comparator Trial Supply

Clinigen CTS

As trial design and execution becomes ever-more complex, initiatives to adapt, increase efficiency and control costs without compromising quality become paramount. Here, Clinigen CTS covers the broad issues and summarises the responses our industry is making in this increasingly demanding landscape.
More info >>

 
Industry Events

Pharma and Device Packaging and Labelling West Coast 2018

27-28 November 2018, Burlingame, CA

The second edition of the Pharma and Device Packaging and Labeling West Coast was a thought-provoking two days of engaging presentations, discussion and networking.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement